Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2021.12.08.471790

Functional modulation of PTH1R activation and signalling by RAMP2

Nemec, K.·Schihada, H.·Kleinau, G.·Zabel, U.·Grushevskyi, E. O.·Scheerer, P.·Lohse, M. J.·Maiellaro, I.
View original source ↗Export metadata ↓

Abstract

Receptor-activity-modifying proteins (RAMPs) are ubiquitously expressed membrane proteins that associate with different G protein-coupled receptors (GPCRs) including the parathyroid hormone 1 receptor (PTH1R), a class B GPCR and an important modulator of mineral ion homeostasis and bone metabolism. However, it is unknown whether and how RAMP proteins may affect PTH1R function. Using different optical biosensors to measure the activation of PTH1R and its downstream signalling, we describe here that RAMP2 acts as a specific allosteric modulator of PTH1R, shifting PTH1R to a unique pre-activated state that permits faster activation in a ligand-specific manner. Moreover, RAMP2 modulates PTH1R downstream signalling in an agonist-dependent manner, most notably increasing the PTH-mediated Gi3 signalling sensitivity. Additionally, RAMP2 increases both PTH- and PTHrP-triggered {beta}-arrestin2 recruitment to PTH1R. Employing homology modelling we describe the putative structural molecular basis underlying our functional findings. These data uncover a critical role of RAMPs in the activation and signalling of a GPCR that may provide a new venue for highly specific modulation of GPCR function and advanced drug design.

Explore related subjects

pharmacology and toxicologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Nemec, K., Schihada, H., Kleinau, G., Zabel, U., Grushevskyi, E. O., Scheerer, P., Lohse, M. J., Maiellaro, I.. 2021-12-10. Functional modulation of PTH1R activation and signalling by RAMP2. https://doi.org/10.1101/2021.12.08.471790

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗
bioRxiv2026

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗
bioRxiv2022

Rudimentary Structure-Activity-Relationship study of the MMV Pathogen Box compound MMV675968 (2,4-diaminoquinazoline) unveils novel inhibitors of Trypanosoma brucei brucei DHFR enzyme

New drugs are urgently needed for the treatment of human African trypanosomiasis (HAT). In line with our quest for dihydrofolate reductase (DHFR) inhibitors in trypanosomes, a small library of analogs of the antitrypanosomal hit (MMV675968) available at MMV as solid materials was screened for antitrypanosomal activity. In silico confirmation of two potent antitrypanosomal analogs as inhibitors of DHFR was achieved, together with elucidation of other antitrypanosomal modes of action. Overall, two analogs of the diaminoquinazoline derivative, MMV675968 reputed to inhibit the enzyme DHFR, displayed approximately 40-fold and 60-fold more potency and selectivity than the parent hit, respectively (MMV1578445 (10): IC50 = 0.045 {micro}M, SI=1737; MMV1578467 (7): IC50 = 0.06 {micro}M; SI=412). Analogs 7 and 10 were also strong binders of the DHFR enzyme, in all their accessible protonation states, and interacted with key DHFR ligand recognition residues Val32, Asp54, and Ile160. MMV1578445 (10) portrayed fast and irreversible trypanosomes growth arrest after 72 h and 4 h at IC99. Analogs 7 and 10 induced ferric iron reduction and DNA fragmentation or apoptosis induction, respectively. The two potent analogs endowed with suitable physicochemical properties are good candidates for further deciphering their potential as starting points for new drug development for HAT. Author summaryAfrican trypanosomiasis is a disease caused by parasites of the Trypanosoma brucei species which affect both humans and animals. We have adopted the fast-track drug repurposing approach to determine the antitrypanosomal activity of the open access MMV Pathogen Box compound library. The compound 2,4-diaminoquinazoline (MMV675998), known as a dihydrofolate reductase (DHFR) inhibitor was identified. Rudimentary structure-activity relationship investigation of this compound unveiled two highly active and selective derivatives MMV1578445 and MMV1578467 which were found to strongly inhibit the Trypanosoma brucei dihydrofolate reductase enzyme in silico. Besides, we demonstrated that analogues MMV1578445 and MMV1578467 could respectively reduce intrinsic ferric iron and induce apoptosis in trypanosomes. The two identified inhibitors of trypanosomes qualify as potential drug candidates that could be useful for future development as novel antitrypanosomal drugs.

pharmacology and toxicology↗